Emerging bioinspired nanomedicines can enhance the STING pathway to target AML cells systemically, and the mechanism may be related to the increased proportion of Th1/Th17 cells, the concentration of IFN-I and proinflammatory cytokines, and the decreased proportion of Th2 cells [149]. Here, STING1 is linked to acute myeloid leukemia.